Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolonging spray.
Popular Articles

Psychiatric Patients Occupy Around 15% Of Total NHS Bed Days
Patients with psychiatric disorders occupy around 15% of total bed days in the NHS - and have a longer length of stay than people with other medical conditions.
generic viagra
Spine-shaped Gold Protrusions Improve The Adherence And Electrical Coupling Of Neurons With The Surface Of Micro-electronic Devices
Interfacing neurons with micro- and nano-electronic devices has been a subject of intense studies over the last decade and is used both in basic research and medical applications. The electronic devices used in such neuroelectronic hybrids are mainly planar metal electrodes and planar transistors.
Zubni implantati
News of the day
Boxers Holyfield, Retta To Participate In HIV/AIDS Charity Fight In Ethiopia
Boxer Evander Holyfield will fight Sammy Retta on July 26 in Ethiopia in an effort to raise money for HIV/AIDS organizations, Reuters India reports. Event organizers hope to raise between $5 million and $10 million from the fight. "I continue to strive to be the very best, but what got me to come here is" HIV/AIDS, Holyfield said, adding, "If we don"t find a cure to this, we"ll be extinct." According to Everton Boland -- CEO of Golden Globe, which is promoting the fight -- a significant portion of money raised will go directly to organizations addressing HIV/AIDS. Organizers said that a group established by African first ladies is the only recipient selected to date but they are considering others (Malone, Reuters India, 5/20).
Oncology

Pharming Receives Agreement On Paediatric Investigation Plan For Rhucin(R) From The EMEA Paediatric Committee

Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMEA) has adopted an opinion agreeing the paediatric investigation plan (PIP) for Rhucin® (recombinant human C1 inhibitor) in the therapeutic area of immunology-rheumatology transplantation. "Agreement of the PIP represents a key milestone in Pharming"s regulatory plans for the September 2009 submission of the Rhucin marketing authorisation application," said Dr. Bruno Giannetti, COO of Pharming. According to the EC Regulation 1901/2006 of 12 December 2006, pharmaceutical companies that submit an application for a marketing authorisation for a medicinal product (MAA) in the EU, have to include an approved PIP as part of the regulatory submission. Pharming Group NV


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009